Duloxetine moderately cost-effective for treating back pain

Duloxetine moderately cost-effective for treating back pain
Duloxetine is a moderately cost-effective treatment for chronic low back pain compared with other post-first-line oral medications, according to research published in the May 15 issue of Spine.

(HealthDay)—Duloxetine is a moderately cost-effective treatment for chronic low back pain (CLBP) compared with other post-first-line oral medications, according to research published in the May 15 issue of Spine.

Ronald Wielage, M.P.H., from Medical Decision Modeling in Indianapolis, and colleagues created a model based on the 2008 osteoarthritis clinical guidelines of the National Institute for Health and Clinical Excellence (NICE). Meta-analysis estimated treatment-specific utilities, and a transfer-to-utility regression was estimated from CLBP trial data. The NICE model and meta-analysis estimated adverse event rates of comparator treatments. Published literature and Quebec and Ontario public sources were used to derive costs.

The researchers found that naproxen, celecoxib, and duloxetine were the most cost-effective in the base case, with naproxen the least expensive medication. Celecoxib had an incremental cost-effectiveness ratio of $19,881, and duloxetine's was $43,437. Other comparators were dominated. Rates of cardiovascular and gastrointestinal adverse events and usage drove up costs. For a population 65 years or older, the incremental cost-effectiveness ratio for duloxetine fell to $21,567, while for a population at higher risk of cardiovascular and gastrointestinal adverse events, it fell to $18,726.

"The model estimates that duloxetine is a moderately cost-effective treatment for CLBP, becoming more cost-effective for populations older than 65 years or at greater risk of cardiovascular and gastrointestinal events," the authors write.

The study was funded in part by Eli Lilly, the manufacturer of duloxetine.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Low-dose duloxetine deemed safe for urinary incontinence

Jul 27, 2012

(HealthDay) -- Duloxetine appears safe for the routine clinical care of women with stress urinary incontinence (SUI), according to a study published online July 23 in the British Journal of Clinical Pharmacology.

Medication duloxetine helps reduce pain from chemotherapy

Apr 02, 2013

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...

Drugs similar in efficacy for neuropathic pain in diabetes

Sep 26, 2012

(HealthDay)—In the treatment of patients with chronic diabetic peripheral neuropathic pain (DPNP), there are no significant differences in pain-relief efficacy between amitriptyline, duloxetine, and pregabalin; however, ...

Recommended for you

Two expats die of MERS in Saudi commercial hub

18 hours ago

Two foreigners died of MERS in the Saudi city of Jeddah, the health ministry said Saturday, as fears rise over the spreading respiratory virus in the kingdom's commercial hub.

UAE reports 12 new cases of MERS

18 hours ago

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

Apr 19, 2014

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

User comments